- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report2014 | Faculty of Medicine in Pilsen
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Second Faculty of Medicine
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop2010 | First Faculty of Medicine
- Lung adenocarcinoma with a rare EGFR mutation and infrequent resistance to treatment2022 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M2007 | Central Library of Charles University
- Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M2007 | Faculty of Medicine in Pilsen
- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Faculty of Medicine in Pilsen
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- EGFR mutations in non-small cell lung cancer - treatment options2019 | Third Faculty of Medicine
- Detection of EGFR Variants in Plasma A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe2018 | Publication without faculty affiliation
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Accounting for EGFR Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data2022 | First Faculty of Medicine
- Long-term surviving patient with EGFR mutation - deletion on exon 79 and acquired resistant mutation T790 - case report2020 | Faculty of Medicine in Pilsen
- Research Report University Hospital of the clinical trial 1200.55Publication without faculty affiliation
- Tumor Rebiopsy - Guide to Targeted Therapy2016 | Faculty of Medicine in Pilsen
- Clinical Significance of Hypermethylation Status in NSCLC: Evaluation of a 30-Gene Panel in Patients with Advanced Disease2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Osimertinib in treating advanced non-squamous non-small cell lung cancer2022 | First Faculty of Medicine
- Tagrisso TM (Osimertinib, AZD929I)2016 | Faculty of Medicine in Pilsen
- Case studies of patients treated with osimertinib2019 | Second Faculty of Medicine
- Modern diagnosis of lung cancer - a task for close multidisciplinary cooperation2011 | Faculty of Medicine in Hradec Králové
- Interdisciplinary consensus for predictive testing of activation mutations of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer2011 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- NSCLC molecular testing in Central and Eastern European countries2018 | Faculty of Medicine in Hradec Králové
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen